CRP relevance in clinical assessment of chronic spontaneous urticaria Tunisian patients

Maouia, Amal; Youssef, M.; Leban, Nadia; Chibani, Jemni Ben; Helal, Ahmed Noureddine; Kassab, Asma

doi:10.1080/15569527.2017.1311338

Cited by 7 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study from Tunisia demonstrated a linear positive correlation between serum CRP levels and urticaria activity scores, and the authors revealed that the anti-inflammatory effects of desloratadine was correlated with serum CRP levels in CSU patients (Maouia et al, 2017). Ohtsuka (2010) found out that the elevated high sensitivity-CRP levels showed good response to oral cyclosporine therapy in CSU.…”

Section: Discussionmentioning

confidence: 99%

“…Numerous studies have established that patients with CSU may have elevated serum CRP levels, and CRP has been proposed to be a possible marker of disease activity, severity, and response to treatments particularly oral antihistamines in CSU (Kolkhir et al, ). A study from Tunisia demonstrated a linear positive correlation between serum CRP levels and urticaria activity scores, and the authors revealed that the anti‐inflammatory effects of desloratadine was correlated with serum CRP levels in CSU patients (Maouia et al, ). Ohtsuka () found out that the elevated high sensitivity‐CRP levels showed good response to oral cyclosporine therapy in CSU.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long‐term effects of omalizumab on peripheral blood cells and C‐reactive protein levels in patients with chronic spontaneous urticaria

Akdoğan

Öğüt

Doğan

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Omalizumab's mechanism of action is not well‐understood yet despite its strong therapeutic efficacy in chronic spontaneous urticaria (CSU). To determine the overall effect of omalizumab on peripheral blood cell counts and serum C‐reactive protein levels (sCRP) during a 1‐year follow‐up in patients with CSU. Data of 74 patients (male/female: 20/54) were reviewed from medical charts. Leucocyte counts, percentages of peripheral blood cells(lymphocyte, monocyte, neutrophil [PPBN], eosinophil, basophil [PPBB]) and sCRP were recorded at baseline, 3rd, 6th, 12th months of omalizumab treatment. Although a dramatic increase in the mean PPBB (±SD) was observed at the 3rd month, PPBB (%) gradually decreased after the 3rd month (PPBB: 0.38 ± 0.21 [baseline] vs. 0.59 ± 0.3 [3rd month], p = .002). However, 12th month PPBB remained higher than baseline (PPBB:0.38 ± 0.21 [baseline] vs. 0.46 ± 0.27 [12th month], p = .03). A dramatic decrease in the mean PPBN (%) was noticed within the first 3 months (PPBN:62.85 ± 8.97 [baseline] vs. 58.37 ± 9.07 [3rd month], p = .04), and 12th month PPBN remained lower than baseline values (PPBN: 62.85 ± 8.97 [baseline] vs. 60.31 ± 8.02 [12th month], p = .045).Mean sCRP (mg/dL) decreased rapidly within the first 3 months (sCRP: 1.09 ± 1.53 [baseline] vs. 0.56 ± 0.45 [3rd month], p = .17) and 12th month sCRP still remained lower than baseline levels (sCRP: 1.09 ± 1.53 [baseline] vs. 0.83 ± 1.06 [12th month], p = .01). Omalizumab substantially increases PPBB,and reduces PPBN accompanied by a reduction in sCRP especially in the first 3 months; however, these effects may continue in the long‐term. The alterations in peripheral blood cell ratios and sCRP may contribute to the therapeutic effect of omalizumab in CSU.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Long‐term effects of omalizumab on peripheral blood cells and C‐reactive protein levels in patients with chronic spontaneous urticaria

Akdoğan

Öğüt

Doğan

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Blood levels of IgG-anti-FceRI, IgG anti-IGE, total IgE, IgE anti-self and other autoantibodies, and autologous serum skin testing are important [71-74]. There are recent data linking low basophil counts with more rapid resolution in children [75]. The clinical history should guide the need for additional tests, given the link to coeliac disease, rheumatoid arthritis and diabetes [76].…”

Section: Laboratory Investigationsmentioning

confidence: 99%

Chronic Urticaria: An Overview of Treatment and Recent Patents

Hon

Leung

et al. 2019

IAD

View full text Add to dashboard Cite

Background: Up to 1% of the general population in the USA and Europe suffer from chronic urticaria (CU) at some point in their lifetime. CU has an adverse effect on the quality of life. Objectives: This study aims to provide an update on the epidemiology, pathogenesis, clinical manifestations, diagnosis, aggravating factors, complications, treatment and prognosis of CU. Methods: The search strategy included meta-analyses, randomized controlled trials, clinical trials, reviews and pertinent references. Patents were searched using the key term "chronic urticaria" at the following links: www.google.com/patents, www.uspto.gov, and www.freepatentsonline.com. Results: CU is a clinical diagnosis, based on the episodic appearance of characteristic urticarial lesions that wax and wane rapidly, with or without angioedema, on most days of the week, for a period of six weeks or longer. Triggers such as medications, physical stimuli, and stress can be identified in 10 to 20% of cases. C-reactive protein/erythrocyte sedimentation rate, and complete blood cell count with differential are the screening tests that may be used to rule out an underlying disorder. The mainstay of therapy is reassurance, patient education, avoidance of known triggers, and pharmacotherapy. Secondgeneration H1 antihistamines are the drugs of choice for initial therapy because of their safety and efficacy profile. If satisfactory improvement does not occur after 2 to 4 weeks or earlier if the symptoms are intolerable, the dose of second-generation H1 antihistamines can be increased up to fourfold the manufacturer’s recommended dose (all be it off license). If satisfactory improvement does not occur after 2 to 4 weeks or earlier if the symptoms are intolerable after the fourfold increase in the dosage of second-generation H1 antihistamines, omalizumab should be added. If satisfactory improvement does not occur after 6 months or earlier if the symptoms are intolerable after omalizumab has been added, treatment with cyclosporine and second-generation H1 antihistamines is recommended. Short-term use of systemic corticosteroids may be considered for acute exacerbation of CU and in refractory cases. Recent patents for the management of chronic urticaria are also discussed. Complications of CU may include skin excoriations, adverse effect on quality of life, anxiety, depression, and considerable humanistic and economic impacts. On average, the duration of CU is around two to five years. Disease severity has an association with disease duration. Conclusion: CU is idiopathic in the majority of cases. On average, the duration of CU is around two to five years. Treatment is primarily symptomatic with second generation antihistamines being the first line. Omalizumab has been a remarkable advancement in the management of CU and improves the quality of life beyond symptom control.

show abstract

“…[ 23 ] We have previously found the involvement of oxidative stress in CSU pathogenesis. [ 24 ] One of the most important aspects of the current study is the improvement of patients' antioxidant status after taking desloratadine 5 mg daily revealed by antioxidant enzyme activities and TAS. Desloratadine was shown to exert a protective effect against oxidative stress in human erythrocytes.…”

Section: Discussionmentioning

confidence: 99%

Desloratadine efficacy in relation to GSTM1 and GSTT1 polymorphic genes in chronic spontaneous urticaria

et al. 2022

View full text Add to dashboard Cite

Background: The etiopathogeny of chronic spontaneous urticaria (CSU) is not well defined. Allelism in glutathione S-transferase GSTM1 and GSTT1 has been suggested as a risk factor. Desloratadine is the first-line treatment for this disease. Objective: This study aimed to investigate the efficacy of a first-line treatment: desloratadine 5 mg/day on antioxidant status and clinical assessment in Tunisian patients with CSU and to identify possible associations between GSTT1 and GSTM1 genotypes and susceptibility to CSU. Methods: Sixty patients with CSU and 60 age- and gender-matched healthy controls were included in the study. We calculated the urticaria activity score (UAS) and assessed the antioxidant parameters (total antioxidant status [TAS], glutathione S-transferase [GST], SOD, CAT, GPx]). Multiplex PCR was performed to find the relationship between GSTM1 and GSTT1 polymorphisms with CSU susceptibility. Results: At baseline, GST, GPx, CAT, SOD activities, and TAS were significantly lower in CSU patients compared to healthy controls ( P < 0.05). After treatment, GST, GPx, CAT, SOD activities and TAS were significantly increased in patients compared to those before treatment ( P < 0.001). We observed a significant association in null alleles of GSTM1. Before treatment, GST activity was significantly lower in patients having GSTM1 + genotype than those having GSTM1 - genotype ( P = 0.001). After treatment, TAS and antioxidant enzymes GST, GPx, SOD, and CAT were significantly elevated in patients having GSTM1 - genotype than those having GSTM1 + genotype ( P < 0.05). Conclusion: These results suggest the impact of GSTM1 and GSTT1 on CSU susceptibility and desloratadine efficacy in Tunisian patients.

show abstract

CRP relevance in clinical assessment of chronic spontaneous urticaria Tunisian patients

Abstract: Desloratadine exerted anti-inflammatory and antioxidant effects on CSU patients revealed by CRP. Patients' remission was synergistic to CRP attenuation emphasizing CRP relevance for CSU clinical assessment.

Cited by 7 publications

References 29 publications

Long‐term effects of omalizumab on peripheral blood cells and C‐reactive protein levels in patients with chronic spontaneous urticaria

Long‐term effects of omalizumab on peripheral blood cells and C‐reactive protein levels in patients with chronic spontaneous urticaria

Chronic Urticaria: An Overview of Treatment and Recent Patents

Desloratadine efficacy in relation to GSTM1 and GSTT1 polymorphic genes in chronic spontaneous urticaria

Contact Info

Product

Resources

About